144 related articles for article (PubMed ID: 30807562)
1. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Yu K
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
[No Abstract] [Full Text] [Related]
2. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Lima CMSR
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):3-5. PubMed ID: 30807559
[No Abstract] [Full Text] [Related]
3. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
[No Abstract] [Full Text] [Related]
4. New guideline-sanctioned and emerging interventions for pancreatic cancer.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):7-9. PubMed ID: 30807561
[No Abstract] [Full Text] [Related]
5. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma.
Bekaii-Saab T; Yu K; Lima CMSR; Wolin EM
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):1-16. PubMed ID: 30807558
[No Abstract] [Full Text] [Related]
7. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
[TBL] [Abstract][Full Text] [Related]
8. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Salvia R; Malleo G; Maggino L; Milella M; Bassi C
Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
[No Abstract] [Full Text] [Related]
10. Combined treatment for locally advanced pancreatic cancer.
Das M
Lancet Oncol; 2019 Jul; 20(7):e351. PubMed ID: 31178373
[No Abstract] [Full Text] [Related]
11. [Diagnostics and therapy of pancreatic carcinoma].
Wenzel P; von Figura G
Dtsch Med Wochenschr; 2021 Feb; 146(4):246-252. PubMed ID: 33592660
[TBL] [Abstract][Full Text] [Related]
12. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Wang M; Zhu P; Chen Z; Yang L
Anticancer Drugs; 2022 Jan; 33(1):e686-e691. PubMed ID: 34459461
[TBL] [Abstract][Full Text] [Related]
13. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
Kondo T; Kanai M; Matsubara J; Quy PN; Fukuyama K; Yamamoto Y; Yamada T; Nishigaki M; Minamiguchi S; Takeda M; Nishio K; Matsumoto S; Muto M
Pancreas; 2020; 49(10):e101-e103. PubMed ID: 33017331
[No Abstract] [Full Text] [Related]
14. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Wu AA; Bever KM; Ho WJ; Fertig EJ; Niu N; Zheng L; Parkinson RM; Durham JN; Onners B; Ferguson AK; Wilt C; Ko AH; Wang-Gillam A; Laheru DA; Anders RA; Thompson ED; Sugar EA; Jaffee EM; Le DT
Clin Cancer Res; 2020 Oct; 26(19):5129-5139. PubMed ID: 32591464
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Busch E; Werft W; Bougatf N; Hackert T; Jäger D; Springfeld C; Berger AK
Pancreas; 2021 Mar; 50(3):300-305. PubMed ID: 33835959
[TBL] [Abstract][Full Text] [Related]
17. The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Rahman M; Washington L
J Med Case Rep; 2019 Jun; 13(1):178. PubMed ID: 31182138
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous regression of pancreatic cancer with liver metastases.
Saade Lemus P; Anderson K; Smith M; Bullock A
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31154349
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer.
Assi HA; Shikdar S; Alhyari L; Aljumaily R
Pancreas; 2020 Oct; 49(9):e95-e96. PubMed ID: 33003100
[No Abstract] [Full Text] [Related]
[Next] [New Search]
